Diamorphine supplies remain low

Diamorphine should still be reserved for palliative care |
NHS supplies of diamorphine will remain low until the end of March, the Department of Health confirmed this week.
The DoH has repeated its advice to health professionals to prescribe
morphine instead and to keep any diamorphine for use in palliative care.
The drug shortage first came to light at the end of December last year
and, according to the DoH, the situation has not changed.
Hospital pharmacists said this week that they still had some supplies
of diamorphine which they were using as advised by the DoH and were continuing
to prescribe morphine as an alternative when appropriate.
Chief pharmacist at the Whittington Hospital, London Malcolm Bubb said: “We
are restricting diamorphine to palliative care patients as recommended
by the chief medical officer and pretty much everybody else has been
switched to morphine. Our only worry is that morphine supplies might
not hold up.
“I think our diamorphine should last us up to another three weeks.”
Helen Howe, chief pharmacist at Addenbrooke’s Hospital in Cambridge,
added: “We moved patients to morphine as soon as we got the advice
so we do not have any stock problems at the moment, although morphine
supplies have not been easy for the past year.
“One of the problems is that diamorphine is much more soluble than
morphine so using morphine as an alternative can be difficult if you
need to give
large doses. Clinically though there is no difference between the two
and we are in fact one of the few countries still offering patients diamorphine.”
A DoH spokeswoman said: “We always said that diamorphine supplies
would be critical in January and February until we get further supplies
at the end of March. That position has not changed.”
The NHS relies on two UK suppliers Chiron, which is its main source,
and Wockhardt UK. She said: “These are the only two suppliers in
the UK so we are totally reliant on them.”
The spokeswoman said the shortage of diamorphine was exceptional but
that there were four morphine alternatives that can be prescribed instead.
Morphine stocks were not expected to run low, she added.
DTB review Use of opioid analgesics for cancer-related pain
in primary care is
reviewed in this month’s Drug and Therapeutics Bulletin (2005;43:9).
The authors suggest that specialist advice should be sought before attempting
to
switch opioid analgesics.
|
|